Characteristics, comorbidities, and treatment practices of lichen planus in Northern Finland: A register-based study among 619 subjects.
comorbidity
epidemiology
health registry data
lichen planus
treatment
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
04
04
2023
revised:
03
05
2023
accepted:
30
05
2023
medline:
12
6
2023
pubmed:
12
6
2023
entrez:
12
6
2023
Statut:
epublish
Résumé
Lichen planus (LP) is a common itching skin disease where lesions appear on the skin and mucous membranes. However, the epidemiology of LP is not yet sufficiently understood. The aim of this study was to retrospectively map out the characteristics, comorbidities and treatments of patients diagnosed with LP. This is a retrospective hospital patient registry-based study performed between 2009 and 2021 in a secondary care hospital (Oulu University Hospital) in Northern Finland. All patients with recorded diagnosis of LP were included in the study. Characteristics, comorbidities, and treatments of LP patients were studied. In total, 619 patients were verified from the hospital health records. The mean age of patients was 54.2 years and the majority were female (58.3%). Most of the patients had symptoms in more than two skin areas (mean 2.7 skin areas), lower limbs being the most common site (74.0%). A third of patients (34.7%) had oral LP lesions. Nearly fifth (19.4%) of the subjects had a history of previous LP. Of comorbidities found among LP subjects, obesity (22.5%), malignancies (19.4%), depression (12.8%), and thyroiditis (12.4%) were seen more often than in general Finnish population. The most used form of treatment was topical corticosteroids (97.6%), followed by phototherapy 26.8%. Systemic treatments such as prednisolone and methotrexate had been used in 7.6% and 1.1% of the patients, respectively. LP patients had a heightened risk for several comorbidities, which should be considered when managing patients with LP.
Sections du résumé
Background and Aims
UNASSIGNED
Lichen planus (LP) is a common itching skin disease where lesions appear on the skin and mucous membranes. However, the epidemiology of LP is not yet sufficiently understood. The aim of this study was to retrospectively map out the characteristics, comorbidities and treatments of patients diagnosed with LP.
Methods
UNASSIGNED
This is a retrospective hospital patient registry-based study performed between 2009 and 2021 in a secondary care hospital (Oulu University Hospital) in Northern Finland. All patients with recorded diagnosis of LP were included in the study. Characteristics, comorbidities, and treatments of LP patients were studied.
Results
UNASSIGNED
In total, 619 patients were verified from the hospital health records. The mean age of patients was 54.2 years and the majority were female (58.3%). Most of the patients had symptoms in more than two skin areas (mean 2.7 skin areas), lower limbs being the most common site (74.0%). A third of patients (34.7%) had oral LP lesions. Nearly fifth (19.4%) of the subjects had a history of previous LP. Of comorbidities found among LP subjects, obesity (22.5%), malignancies (19.4%), depression (12.8%), and thyroiditis (12.4%) were seen more often than in general Finnish population. The most used form of treatment was topical corticosteroids (97.6%), followed by phototherapy 26.8%. Systemic treatments such as prednisolone and methotrexate had been used in 7.6% and 1.1% of the patients, respectively.
Conclusion
UNASSIGNED
LP patients had a heightened risk for several comorbidities, which should be considered when managing patients with LP.
Identifiants
pubmed: 37305152
doi: 10.1002/hsr2.1327
pii: HSR21327
pmc: PMC10256618
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1327Informations de copyright
© 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Arch Dermatol Res. 2023 Mar;315(2):139-146
pubmed: 36471086
Soc Sci Med. 1987;25(5):507-13
pubmed: 3672148
Int J Cancer. 2018 Jan 1;142(1):18-22
pubmed: 28857160
Int J Dermatol. 2009 Jul;48(7):682-94
pubmed: 19570072
J Affect Disord. 2015 Mar 1;173:73-80
pubmed: 25462399
J Dtsch Dermatol Ges. 2022 Aug;20(8):1101-1110
pubmed: 35913102
J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1570-5
pubmed: 25545122
Skin Health Dis. 2021 Jun 05;1(3):e53
pubmed: 35663141
Acta Derm Venereol. 2020 Nov 24;100(18):adv00330
pubmed: 33047148
Acta Derm Venereol. 2021 Jul 30;101(7):adv00508
pubmed: 34230981
N Engl J Med. 2012 Feb 23;366(8):723-32
pubmed: 22356325
J Am Acad Dermatol. 2019 Dec;81(6):1397-1399
pubmed: 31004729
Eur J Clin Pharmacol. 2011 Jan;67(1):73-7
pubmed: 20809083
J Am Acad Dermatol. 2018 Nov;79(5):789-804
pubmed: 30318136
J Am Acad Dermatol. 2002 Feb;46(2):207-14
pubmed: 11807431
ScientificWorldJournal. 2014 Jan 30;2014:742826
pubmed: 24672362
Arch Dermatol Res. 2023 Mar;315(2):317
pubmed: 36773098
Arch Dermatol. 2009 Sep;145(9):1040-7
pubmed: 19770446
Front Med (Lausanne). 2021 Nov 01;8:737813
pubmed: 34790675
J Dtsch Dermatol Ges. 2013 Apr;11(4):309-19
pubmed: 23320493